CooperCompanies (COO) Q3 2026 earnings review
Record Cash Flow Masked by Vision Contraction and Guidance Cuts
Management highlighted a quarter of 'earnings exceeding expectations,' but the top-line data reveals a harsh deceleration. CooperVision (CVI) organic growth flatlined at 0% in Q3 and is guided negative for Q4 due to an abrupt 'U.S. channel inventory reduction.' Furthermore, the highly anticipated strategic review of the Surgical unit (CSI) ended with a whimper—retaining the asset and appeasing shareholders with a massive $3 billion buyback authorization. With full-year revenue and EPS guidance slashed from Q2 levels, the operational engine is sputtering even as financial engineering accelerates.
🐂 Bull Case
Free Cash Flow surged 66% YoY to $273 million, validating the multi-year thesis that declining CapEx post-MyDay capacity expansion will yield massive cash. Management reaffirmed the $2.2B+ FY26-FY28 target.
Management executed a massive pivot in capital allocation, repurchasing $339 million (4.9M shares) in Q3—up from just $13 million in Q2. The authorization was expanded to $3 billion, providing a strong floor for EPS.
🐻 Bear Case
The core franchise flatlined at 0% organic growth in Q3 and is guided to contract 0-2% in Q4. Weakness has spread from APAC to the Americas (-2%), driven by unexpected US channel destocking.
Despite buying back 4.9 million shares, management chopped FY26 Non-GAAP EPS guidance to $4.51-$4.55 (down from $4.58-$4.66 in Q2), highlighting severe underlying operational deleverage.
⚖️ Verdict: 🔴
Bearish. The free cash flow inflection is real and impressive, but you are buying a medical technology company for growth. A negative growth guide for the core Vision segment and a slashed full-year EPS target contradict the rosy PR narrative.
Key Themes
Vision Segment Growth Reversing on US Weakness
CVI organic growth decelerated abruptly to 0%. The Americas segment, previously a stronghold balancing out APAC weakness, fell 2%. Management blamed 'U.S. channel inventory reduction,' which will drag Q4 organic growth down to -2% to 0%. This data point directly contradicts management's earlier narrative of accelerating growth driven by new MyDay contract wins.
The 'Absurd' Valuation Narrative Fizzles
In Q2, the CEO hyped the CooperSurgical strategic review, claiming the public valuation was 'absurd' and that 'multiple parties' were highly interested in buying the entire asset. Fast forward three months: the board unanimously concluded to retain CSI. While they expanded the buyback to appease investors, the failure to monetize the asset at a premium raises serious questions about market appetite and the division's standalone quality.
Financial Engineering Accelerates
Capital returns have replaced organic growth as the primary driver of shareholder value. Q3 buybacks hit $339.1 million (4.9 million shares), dwarfing the $13 million spent in Q2 and $92 million in Q1. With a fresh $3 billion authorization remaining, the company is using its newly unlocked cash flow to aggressively defend the stock price.
Slashed Fiscal 2026 Guidance Contradicts Optimism
The press release quotes the CEO praising 'earnings exceeding expectations.' The raw data tells a different story. Management quietly cut FY26 revenue guidance to $4.229-$4.252 billion (from $4.285-$4.321 billion in Q2). Crucially, Non-GAAP EPS was chopped to $4.51-$4.55 (from $4.58-$4.66). Given the massive 4.9M share retirement in Q3, the underlying operational EPS cut is far more severe than the headline numbers imply.
Macro: Fertility Stabilization
CooperSurgical (CSI) was the sole bright spot, generating 3% organic growth. The Fertility sub-segment grew 5% organically to $141.2 million. This indicates a normalization of the broader macroeconomic IVF market, which had previously suffered from delayed clinic capital purchases and patient cycle softness in international markets.
Other KPIs
Stable. Up 30 basis points YoY. Despite the top-line struggles and unfavorable foreign exchange, disciplined expense management and synergies from prior reorganization efforts successfully protected profitability.
GAAP EPS spiked artificially compared to $0.49 last year, driven entirely by a $307.2 million discrete tax benefit following the favorable completion of a U.K. tax examination. Investors must focus strictly on the $1.15 Non-GAAP EPS to gauge actual operational performance.
Guidance
Decelerating. Implies 2% to 3% organic growth. This is a severe cut from the 3.5% to 4.5% organic growth guided in Q2, entirely driven by the collapse in CooperVision demand and inventory destocking.
Reversing. Implies organic contraction of -2% to 0%. The US channel destocking creates a significant near-term headwind for the core franchise, wiping out the momentum from previously touted MyDay contract wins.
Decelerating. Chopped from the $4.58-$4.66 range provided just three months ago. With an aggressive share count reduction executing in Q3, this cut points to significant margin pressure or volume deleverage in Q4.
Accelerating. Implies healthy 4% to 6% organic growth. With the strategic review overhang removed, the segment appears to be normalizing well against easier comps.
Key Questions
The Sudden US Destocking
What exactly drove the sudden need to reduce U.S. channel inventory in the Vision segment, and why wasn't this risk identified during the Q2 call just three months ago?
Failed Strategic Review
Given the robust 'multiple party' interest previously cited for the Surgical business, what specific valuation gaps or operational findings caused the strategic review to end in retention rather than a sale?
Magnitude of the EPS Cut
You repurchased 4.9 million shares in Q3, which should mathematically boost Q4 EPS. Despite this, full-year EPS guidance was cut by ~10 cents. Can you bridge exactly how much operational deleverage or FX headwind is hiding behind this lowered guide?